These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 21816688)
1. Managing refractory metastatic renal cell carcinoma: a RECORD spinning on a tilted AXIS. Pal SK; Vogelzang NJ Clin Genitourin Cancer; 2011 Sep; 9(1):3-5. PubMed ID: 21816688 [No Abstract] [Full Text] [Related]
2. Axitinib in the treatment of metastatic renal cell carcinoma. Ho TH; Jonasch E Future Oncol; 2011 Nov; 7(11):1247-53. PubMed ID: 22044199 [TBL] [Abstract][Full Text] [Related]
3. Tumour flare during interruption of temsirolimus treatment for metastatic renal cell cancer. Paterson C; Jones RJ Clin Oncol (R Coll Radiol); 2009 Nov; 21(9):732-3. PubMed ID: 19665360 [No Abstract] [Full Text] [Related]
4. Axitinib (Inlyta) for advanced renal cell carcinoma. Med Lett Drugs Ther; 2012 Jun; 54(1392):47-8. PubMed ID: 22683928 [No Abstract] [Full Text] [Related]
5. Active tuberculosis during temsirolimus and bevacizumab treatment. Lin CC; Wang JY; Pu YS J Clin Oncol; 2013 Jan; 31(2):e18-20. PubMed ID: 23169507 [No Abstract] [Full Text] [Related]
7. Endobronchial metastases from renal cell carcinoma: a late manifestation of the disease with an increasing incidence. Khattak MA; Fisher RA; Pickering LM; Gore ME; Larkin JM BJU Int; 2012 Nov; 110(10):1407-8. PubMed ID: 22937754 [No Abstract] [Full Text] [Related]
8. Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? Goldstein R; Pickering L; Larkin J Expert Rev Anticancer Ther; 2010 Oct; 10(10):1545-57. PubMed ID: 20942625 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma. Rini BI; Wilding G; Hudes G; Stadler WM; Kim S; Tarazi J; Rosbrook B; Trask PC; Wood L; Dutcher JP J Clin Oncol; 2009 Sep; 27(27):4462-8. PubMed ID: 19652060 [TBL] [Abstract][Full Text] [Related]
12. The application of the National Institute of Clinical Excellence guidelines for treatment of metastatic renal cell carcinoma in the United Kingdom: friend or foe? Powles T; Jones R; Chowdhury S; Shamash J; Mantle M; Lim L; Hutson T BJU Int; 2010 Aug; 106(4):453-7. PubMed ID: 20576026 [No Abstract] [Full Text] [Related]
13. Temsirolimus (Torisel) for advanced renal cell carcinoma. Med Lett Drugs Ther; 2007 Dec; 49(1276):103-4. PubMed ID: 18084154 [No Abstract] [Full Text] [Related]
14. Prolonged response to temsirolimus in a pre-treated patient with metastatic renal cell carcinoma and poor performance status. Jafri M; Douis H; Porfiri E Clin Oncol (R Coll Radiol); 2008 Oct; 20(8):657-8. PubMed ID: 18644704 [No Abstract] [Full Text] [Related]
16. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors. Chan HY; Grossman AB; Bukowski RM Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346 [TBL] [Abstract][Full Text] [Related]
17. Are we really making an advance in the treatment of metastatic renal cell carcinoma? Kirkali Z Eur Urol; 2006 Apr; 49(4):604-5. PubMed ID: 16481098 [No Abstract] [Full Text] [Related]
18. Metastatic renal cell carcinoma: role of mammalian target of rapamycin inhibitors. Bukowski RM Clin Genitourin Cancer; 2007 Sep; 5(6):359-61. PubMed ID: 17956708 [No Abstract] [Full Text] [Related]
19. Kidney cancer: Axitinib destined for second place? Payton S Nat Rev Urol; 2013 Dec; 10(12):678. PubMed ID: 24217676 [No Abstract] [Full Text] [Related]
20. Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma. Korhonen P; Zuber E; Branson M; Hollaender N; Yateman N; Katiskalahti T; Lebwohl D; Haas T J Biopharm Stat; 2012; 22(6):1258-71. PubMed ID: 23075021 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]